Table I.

Islet allograft survival across MHC or minor histocompatibility barriersa

DonorsRecipientsnBarriersTreatmentSurvival (days)MST
BALB/cBALB/c4SyngeneicNone>120, >120, >120, >120>120
B10.BRBALB/c5MHC+bNone12, 14, 15, 17, 1715
B10.BRBALB/c5MHC+bControl Ab14, 15, 17, 17, 1717
B10.BRBALB/c5MHC+bAnti-IL-1212, 12, 13, 13, 1713
DBA/2JB6AF16Partial MHCControl Ab14, 16, 17, 18, 20, 2017
DBA/2JB6AF16Partial MHCAnti-IL-1220, 22, 22, 26, 28, 3525
B10.BRCBA/ca4MinorNone>120, >120, >120, >120>120
B10.D2BALB/c5MinorNone15, 16, 17, 19, 2117
B10.D2BALB/c6MinorAnti-IL-1220, 23, 25, 28, 35, >10038
DBA/2JBALB/c6MinorNone20, 22, 26, 27, 30, 3126
DBA/2JBALB/c6MinorControl Ab21, 22, 28, 28, 31, 3428
DBA/2JBALB/c10MinorAnti-IL-1268, 70, 82, >120, >120, >120>120
>120, >120, >120, >120
  • a Survival of islet allografts that were transplanted across major or multiple minor histocompatibility barriers. Crude islets from donor mice (300-400 islets) were transplanted under the renal capsule into recipients that had been rendered diabetic by a single i.p. injection of streptozotocin at 5 to 7 days before transplantation. Groups of recipient mice received no treatment or were treated with anti-IL-12 or control Ab (1 mg i.p. on days 0, 1, and 7 postransplant).

  • b MHC+ = MHC and minor histocompatibility barriers.